IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells

BACKGROUND: Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), even though acquired resistance to sorafenib has been found in many HCC patients, resulting in poor prognosis. Accumulating evidence demonstrates that liver cancer stem cells (LCSCs) contribute to...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yu, Chen, Gang, Han, Zhijian, Cheng, Huijuan, Qiao, Liang, Li, Yumin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533247/
https://www.ncbi.nlm.nih.gov/pubmed/33061451
http://dx.doi.org/10.2147/OTT.S262089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533247/
https://www.ncbi.nlm.nih.gov/pubmed/33061451
http://dx.doi.org/10.2147/OTT.S262089

Ejemplares similares